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Introduction
Interaction of antigen (Ag) with the TCR results in either
clonal expansion or unresponsiveness (anergy). This can be
explained by view that T cells require two signals for activa-
tion. The first signal is delivered via TCR occupancy, which
alone fails to induce complete T cell activation, whereas a
TCR signal plus a second or ‘costimulatory’ signal derived
from APC causes activation. The best accepted and most 
rigorously characterized costimulatory molecules are now
considered to be the family of B7 proteins (B7-1 and B7-2).
B7 proteins are found on APC1,2 and their receptor CD28 is
expressed on T cells.3–5 B7 costimulation in the presence of
a TCR signal results in up-regulation of the IL-2 receptor 
(IL-2R) a , b , and g chains,6–9 cytokine transcription,10–13 T
cell proliferation14–16 and expression of Bcl-xL.17 A diagram-
matic illustration of the two-signal model of T cell activation
is shown in Fig. 1.
A second receptor on T cells for B7 has now been
described.18 This molecule is called cytotoxic T lymphocyte-
associated molecule-4 (CTLA-4) and is thought to negatively
regulate T cell responses.19 The CTLA-4 molecule is not
found on the surface of resting T cells but is up-regulated 
following T cell activation.11,18,20 Indeed, CD28 signalling can
lead to increased levels of CTLA-4 mRNA.20
The role of B7 costimulatory signals in T cell activation
has been intensely studied, both in vitro and in vivo. A com-
monly used B7 antagonist used for these studies is CTLA4-
Ig. The CTLA4-Ig fusion protein consists of the extracellular
portion of CTLA-4 and the Fc portion of human IgG. 
Similarly, antibodies against B7-1 and/or B7-2 can be used to
block B7 costimulation. Alternatively, the generation of
CTLA4-Ig transgenic mice and CD28-, B7-1-, B7-2-, and
B7-1/B7-2-deficient mice has provided a direct means to
investigate the function of these molecules both in vivo and
in vitro. Lastly, anti-CD28 mAb has been found to induce a
costimulatory signal in vitro and has been used extensively to
deliver optimal CD28 signals to cultured T cells receiving
suboptimal TCR stimulation.
Structure and expression of the CD28 and B7
molecules
CD28 and CTLA-4
The CD28 glycoprotein is expressed on virtually 100% of
murine T cells, all human CD4+ T cells and about 50% of
human CD8+ T cells.5,21 Although CD28 is expressed consti-
tutively, its levels increase after T cell activation.22 CD28 is
also highly expressed on developing thymocytes,23 although
its role in thymocyte selection is not well understood. The
CTLA-4 molecule is expressed on the surface of activated
CD4+ and CD8+ T cells. However, unlike CD28, CTLA-4 is
not expressed on the surface of resting T cells. Moreover,
CTLA-4 expression on activated T cells is only 2–3% of the
levels of CD28.24 Both CD28 and CTLA-4 exist as disulphide-
linked homodimeric glycoproteins.5,22,24,25 However, a few
studies have suggested that these molecules can also exist in
monomeric form.26,27 The ligands for CD28 and CTLA-4 are
B7-1 (CD80) and B7-2 (CD86), which are expressed on a
variety of APC.
CD28 and CTLA-4 have single extracellular Ig-like
domains containing CDR1, CDR2 and CDR3 loops. The
highest concentration of conserved residues in CD28 and
CTLA-4 is the hexapeptide MYPPPY motif in the CDR3-like
loop.28 Mutagenesis studies have shown that these residues
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are important for binding to B7-1 and B7-2.28 Numerous
studies have shown that CD28 has a lower avidity than
CTLA-4 for B7-1 and B7-2.29,30 B7-1 and B7-2 bind to
CTLA4-Ig with similar avidities, but they differ slightly in
their dissociation rates. The half-maximal dissociation time
for 125I-CTLA4-Ig binding to B7-2 Chinese Hamster Ovary
cells (CHO) was 2.5–6 min, while the half-maximal dissoci-
ation time for B7-1 CHO was 19–28 min.29 B7-1 and B7-2
must use different binding determinants upon interaction
with the CDR3 region of CTLA4-Ig, as predicted by the >200
fold difference in the ability of B7-1 and B7-2 to bind a
CTLA4-Ig mutant (Y100A-Ig) that carries a mutation in the
MYPPPY motif.29
B7-1 and B7-2: Ligands for CD28 and CTLA-4
The two distinct CD28 ligands, B7-1 and B7-2, appear to be
only distantly related, with an amino acid sequence identity
of 26%.31 Lipopolysaccharide-dextran sulphate-stimulated
splenocytes from mice deficient for both B7-1 and B7-2 lack
any detectable binding to mCTLA4-Ig, indicating that there
are no further ligands for CTLA-4.32 B7-1 and B7-2 exist as
monomers and have an extracellular V-like and a C-type
domain. Conserved residues in B7-1 and B7-2 found in these
V-and C-like domains have been found to be critical for the
binding activity of B7-1 to CD28 and CTLA-4.33
The most marked differences between B7-1 and B7-2 are
found in the cytoplasmic tail. B7-1 has a very short cyto-
plasmic tail, while the cytoplasmic tail of B7-2 is much
longer and contains three potential sites for phosphorylation
by protein kinase C (PKC).34 However, much of the homol-
ogy between human and murine B7-1 is concentrated in the
Ig-like extracellular domains and not in the cytoplasmic tail.
This indicates that B7-2 may not have an important signalling
role, but may rather act primarily as a ligand.25
B7-2 is constitutively expressed on resting monocytes and
dendritic cells (DC) in vitro and is up-regulated rapidly after
activation of monocytes, DC, Langerhans cells (LC), B cells
and T cells.35–38 In contrast, B7-1 shows very little constitu-
tive expression on any cell type. However, B7-1 is up-
regulated on monocytes, DC, LC, B cells and T cells follow-
ing activation in vitro.35,39–42 B7-2 is generally expressed
more rapidly and to a higher level than B7-1. For example,
B7-2 is more rapidly expressed than B7-1 following B-cell
activation.43,44 In addition, Inaba et al.37 noted that B7-2 was
the main (> 90%) CTLA4-Ig ligand on murine DC and was
largely responsible for the ability of DC to activate T cells.
Many factors have been found to regulate the expression
of B7-1 and B7-2, including mitogens,44 MHC class II liga-
tion,41 surface Ig cross-linking,35,38,45 ligation of CD4046,47
and a variety of cytokines. Interestingly, IFN- g has been
shown to increase B7-2 expression and decrease B7-1 expres-
sion on LC35,40 and on peritoneal macrophages.35 Therefore,
B7-1 and B7-2 expression can be independently regulated by
the same stimulus.
Role of B7 costimulation in primary T cell activation
In vitro studies have indicated that CD28 signalling prevents
T cell anergy.48,49 For example, murine and human IL-2-
producing T cell clones are unresponsive to interaction with
peptide-pulsed metabolically inactive APC that cannot up-
regulate B7 molecules.25 These T cells are anergic, because
they are unable to produce IL-2 when rechallenged with 
costimulatory APC and Ag. However, the anergic state can be
reversed by provision of exogenous IL-2.48 In vivo treatment
of mice with CD28 antagonists has not been demonstrated to
induce anergy, but can suppress humoral responses,50 inhibit
the progression of autoimmune disease and prevent graft
rejection.51–54
Paradoxically, CD28-deficient mice can clear infection
with lymphocytic choriomeningitis virus (LCMV) and reject
some skin grafts.55–57 Therefore, in certain circumstances
naïve T cells can become activated in the absence of CD28.
Our own studies have shown that while B7 costimulation is
required for T cell-dependent eosinophilia in a model of oval-
bumin (OVA)-induced airway inflammation, Th2 cells are
able to develop in CTLA4-Ig treated mice.58 In a second
study, we have found that CTLA4-Ig treatment has little
effect on Th2 cell development or eosinophilia in Nippo-
strongylus brasiliensis-infected mice, although Ab responses
are severely reduced.59 We have concluded from these studies
that the requirement for B7 costimulation during activation of
naïve Th2 cells in vivo is determined by the type of Ag
encountered. The properties of a pathogen or protein Ag 
that lower the requirement for B7 costimulation may include:
(i) high dosage; (ii) complexity; or (iii) ability to induce 
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Figure 1 Two-signal model of T cell activation. T cell activation
requires two signals. The first signal is provided by interaction of
the TCR with antigenic peptide presented on MHC molecules. The
second ‘costimulatory’ signal can only be delivered by APC and is
required for IL-2 production. In the absence of a costimulatory
signal, T cells fail to make IL-2 and may become unresponsive to
further stimulation with antigen. The best-characterized costimu-
latory signal involves the interaction of B7-1/B7-2 on the APC
with CD28 on the T cell.
pro-inflammatory cytokines, such as IL-1, TNF, IL-6, IL-12,
IFN- a and IFN- b .
There are several possible explanations for the observa-
tion that B7 costimulation is not always required for in vivo
T cell activation. First, other costimulatory molecules may be
able to substitute, or complement, CD28–B7 interactions.
Second, B7-independent T-cell activation may occur under
conditions of supraoptimal antigen presentation or TCR
occupancy. In this regard, it has been shown that B7 costim-
ulation causes T cells to become more sensitive to antigenic
stimulation by lowering the number of TCR that need to be
triggered before activation occurs.60,61 Last, CD28 signals
may not be absolutely required for the initiation of T cell acti-
vation, but may instead have a role in sustaining T cell expan-
sion,62 perhaps via the induction of T cell survival genes.
Role of B7 costimulation in the development and
activation of effector and memory T cells
The activation requirements of naïve, effector and memory 
T cells have been well studied using in vitro assays. Naïve 
T cells were found to respond poorly to TCR stimulation
alone and required B7 costimulation in order to become fully
activated.63 In contrast, B7 costimulation is not necessary for
effector T cell activation, although these cells do require B7
costimulation for optimal cytokine production.64 Interest-
ingly, the requirement for B7 costimulation appears to differ
when individual cytokines are studied. For example, in the
study by Dubey et al.64 IL-4 production was B7 independent
and IFN- g production was slightly B7 dependent, while IL-2
and IL-5 production were strongly dependent on B7 costim-
ulation. Activation requirements of memory T cells have been
studied by isolating TCR transgenic T cells from adults that
express memory cell surface markers. Alternatively, memory
T cells are generated by producing effector T cells in vitro
and ‘parking’ these cells in thymectomized, bone marrow
reconstituted adult mice until they return to a resting state.65
Memory T cell activation differs from naïve T cell activation,
in that memory T cell responses to anti-CD3 can be elicited
in the absence of B7 costimulation. However, B7 costimula-
tion enhances memory T cell activation in this system.65
Therefore, B7 costimulatory signals are not necessary for
memory T cell activation, but they do optimize the responses
of these cells.
Differences in the costimulatory requirements of naïve,
effector and memory T cells are reflected in the range of APC
that can activate these cells. For example, naïve T cells only
respond well to DC that express high levels of B7.65,66
However, effector T cells can be stimulated by DC,
macrophages or B cells.65,67 Memory T cells respond best to
DC, but have the ability to respond to other APC, albeit less
well than effector T cells.65,68
Differential activation requirements of naïve, effector
and/or memory T cell populations are likely to have impor-
tant consequences during in vivo immune responses. As dis-
cussed, numerous studies have investigated the role of B7
costimulation in the activation of naïve T cells in vivo.
However, only a few studies have been made regarding the
role of B7 costimulation during in vivo activation of effector
and memory T cells. One study has addressed the role of B7
costimulation in effector T cell activation by treating mice
with CTLA4-Ig after the onset of murine lupus.53 The
CTLA4-Ig-treated mice show a reduction in autoimmune
lupus. However, it was not clear whether effector T cell
responses or activation of newly recruited naïve T cells were
blocked. A later study by Via et al.69 investigated the effect of
CTLA4-Ig treatment during a model of graft-versus-host
disease and found that disease progression is blocked, thus
demonstrating more convincingly that CTLA4-Ig treatment
can inhibit effector T cell responses in vivo.
A study addressing the role of B7 costimulation during
memory T cell activation has shown that CTLA4-Ig inhibits
primary but not memory T cell responses to a gastrointesti-
nal nematode Heligmosomoides polygyrus.70 Conversely,
CTLA4-Ig administered prior to intranasal challenge inhib-
ited airway eosinophilia in a study of Ag-induced lung
inflammation by Keane-Myers et al.71 and in a similar study
carried out in our own laboratory (Harris, unpubl. obs.,
1997). Recently, we have observed that mice treated with
CTLA4-Ig during primary and secondary infection with 
N. brasiliensis exhibit intact memory T cell responses,
although IgE responses are decreased. We have concluded
from these data that the requirement for B7 costimulatory
signals during memory T cell responses in vivo is determined
by the type of Ag encountered, in a similar fashion to primary
T cell responses.
Role of B7 costimulation in Th1/Th2 cell development
and effector function
Mosmann et al.72 have demonstrated that mouse CD4+ T cell
clones can be classified into distinct populations, based on
their patterns of cytokine production. They have termed these
populations Th1 and Th2. Generally, Th1 clones produce 
IL-2, IL-3, IFN- g , TNF- b and granulocyte–macrophage
colony stimulating factor (GM-CSF) and Th2 clones produce
IL-4, IL-5, IL-9, IL-10 and IL-13. A number of in vitro
studies have shown that B7 costimulatory signals promote
Th2 cytokine production over Th1 responses. For example,
King et al.73 stimulated human CD4+ T cells in the presence
of anti-CD28 mAb and found IL-4, IL-5, IL-2 and IFN-g pro-
duction. Strikingly, IL-4 and IL-5 were progressively
enhanced and IL-2 and IFN- g diminished after consecutive
cycles of CD28 ligation. Similarly, Rulifson et al.74 have
found that increasing CD28 ligation during primary culture
of CD4+ TCR transgenic T cells increases production of 
IL-4 and IL-5, but not IFN- g , upon restimulation of these
cells with immobilized anti-CD3 mAb. The data obtained in
this study by Rulifson and colleagues were not the result of
an outgrowth of Th2 cells by increased IL-2 production,
because the addition of exogenous IL-2 could not compensate
for CD28 ligation.
In support of the in vitro studies, several in vivo studies
have noted that blockade of B7 costimulation preferentially
inhibits Th2 cell responses, while leaving Th1 responses
intact. For example, infection with Leishmania major nor-
mally causes susceptible BALB/c mice to develop a deleteri-
ous Th2 response, while resistant C57BL/6 mice develop a
protective Th1 response. Administration of CTLA4-Ig during
Leishmania infection protects BALB/c mice from disease but
has no effect on the immune response in C57BL/6 mice.75
Similarly, CTLA4-Ig treatment resulted in a diminution of
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clinical disease in mice adoptively transferred with experi-
mental allergic encephalomyelitis (EAE)-inducing T cell
clones.54 Disease prevention was associated with a reduced
production of IL-2 and IL-4 but not IFN- g . Recently,
Lenschow et al.76 bred the non-obese diabetic (NOD) mouse
to mCTLA4-H g 1-transgenic or CD28-deficient backgrounds
and found a dramatic increase in disease incidence and sever-
ity. Increased disease incidence correlated with enhanced 
IL-2 and IFN- g and diminished IL-4.
The role of B7 costimulation during Th1 and Th2 cell dif-
ferentiation has also been studied using models of more
polarized Th1 and Th2 responses. T cell responses to LCMV
(which classically induces a strong Th1 response) are intact
in CD28-deficient mice.57,77 Conversely, CTLA4-Ig treat-
ment abrogates Th2 responses during a model of airway
inflammation71 and after infection with Schistosoma
mansoni78 or H. polygyrus.79
Collectively, the data discussed support the hypothesis
that Th2 responses are more B7 costimulation dependent than
Th1 responses. However, some Th1 responses have been
shown to be highly B7 costimulation dependent. These include
T cell responses to vesicular stomatitis virus (VSV) infec-
tion,77 mouse mammary tumour viruses (MMTV),80 allo-
antigens,51,52,81 soluble Ag50,56 and tumours.82 In addition, 
we have shown that Th2 responses to certain Ag, such as 
N. brasiliensis, can occur in the absence of B7 costimulation.59
In contrast to the priming of naïve T cells, in vitro activa-
tion of effector Th2 cells appears to be less dependent on B7
costimulation than effector Th1 cell activation. Effector Th2
cells only require IL-4 as their growth factor, whereas naïve
T cells and effector Th1 cells require IL-2. Most established
Th1 clones continue to require CD28 signalling to produce
IL-2,63 whereas the production of IL-4 by Th2 effector cells
is relatively B7 costimulation independent.83 However, Th2
clones may require B7 costimulation to respond to IL-4.84
In summary, numerous studies have indicated that in vitro
and in vivo Th2 cell priming is more dependent on B7 cos-
timulation than Th1 cell development. Conversely, activation
of Th2 effector cells is less sensitive to B7 costimulation than
Th1 effector cell activation. Collectively, these data indicate
that the outcome of CTLA4-Ig-induced blockade of B7 
costimulation on an immune response will be complicated by
the nature of immune response (Th1 or Th2) and the timing
of the treatment.
Role of B7 costimulation in humoral immune responses
T cell-dependent B cell responses require that T helper cells
provide the necessary signals for B cell growth and Ig class
switching. These signals are provided in the form of soluble
cytokines and membrane-bound CD40 ligand (CD40L) fol-
lowing T cell recognition of Ag presented by MHC class II
molecules on B cells. Numerous studies have reported an
essential role for B7 costimulation in T cell-dependent
humoral responses. For example, compared with normal
mice, levels of total serum Ig are decreased in unimmunized
mCTLA4-H g 1 transgenic mice. This is true for all Ig iso-
types, except IgA. Interestingly, gut-associated lymphoid
tissue from mCTLA4-H g 1 transgenic mice has normal ger-
minal centres and is probably the source of serum IgA.85
CD28-deficient mice have also been found to exhibit
decreased levels of total serum Ig. However, only IgG1 and
IgG2b have been found to be decreased, while IgG2a levels
remain high.57 This observation supports the proposal that
there is a greater requirement for B7 costimulation during
Th2 responses than for Th1 responses.
B7 costimulatory signals appear to be essential for Ag-
induced Ab production. For example, primary T-dependent
Ab responses to sheep red blood cells (SRBC) or key-hole
limpet haemocyanin (KLH) are inhibited in a dose-dependent
fashion by CTLA4-Ig.50 In addition, mCTLA4-H g 1 trans-
genic mice exhibit reduced primary T-dependent Ab
responses85,86 and lack germinal centre formation85 following
immunization with soluble Ag. Normal Ab levels are not
achieved in mCTLA4-H g 1 transgenic mice, even at long
intervals after Ag immunization or after multiple immuniza-
tions.85 Examination of Ig isotypes in Ag immunized
mCTLA4-H g 1 transgenic mice has found that all isotypes are
lowered. CD28-deficient mice also exhibit decreased 
T-dependent Ab responses.57
Remarkably, mCTLA4-H g 1 transgenic mice that exhibit
lowered Ag-induced Ab production show enhanced expan-
sion of Ag-specific T cells, indicating that B7 costimulation
is more stringently required for B cell responses than for T
cell priming.86 Blockade of B7 costimulation does not alter
the ability of mice to generate normal cytotoxic T cell
responses to LCMV infection.57,87 However, production of
LCMV-specific IgG is decreased 3–20 fold in mCTLA4-H g 1
transgenic mice. In our own studies, we have found that B7
costimulation is required for optimal Ab production in
response to OVA immunization and airway challenge or to 
N. brasiliensis infection.58,59 Interestingly, Th2 cell cytokine
production and blood and airway eosinophilia were only
mildly effected in N. brasiliensis-infected mice, while Ab
responses were severely decreased. Collectively, these data
indicate that humoral responses exhibit a greater requirement
for B7 costimulation than T cell priming, differentiation,
cytotoxicity or cytokine production.
Differential roles for B7-1 and B7-2 in T cell immune
responses
It is unknown, at present, whether costimulatory signals pro-
vided by B7-1 and B7-2 are functionally distinct or over-
lapping. In vitro studies have found that either B7-1 or B7-2
is sufficient, in the absence of the other, to provide some 
costimulatory function.88,89 Nevertheless, other studies have
provided evidence for a preferential role for B7-1 or B7-2
during T cell immune responses, even when both are
expressed by the stimulatory APC. For example, Razi-Wolf
et al.90 have shown that T cell proliferation to concanavalin 
A (Con A) or alloantigen is solely dependent on B7-1. In
addition, Fleischer et al.39 have demonstrated that T cell acti-
vation by human monocytes is inhibited by anti-B7-1 but 
not anti-B7-2, despite higher expression of B7-2 relative to 
B7-1. Conversely, Hathcock et al.35 have found that T cell
proliferation to allogeneic APC or soluble anti-CD3 pre-
sented by B cells is highly B7-2 dependent, with little (if any)
dependence on B7-1.
More recently, B7-1- and B7-2-deficient mice have been
generated. Mice deficient for both B7-1 and B7-2 fail to gen-
erate Ag-specific IgG1 and IgG2a responses. However, mice
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lacking only B7-1 or B7-2 mount high titre Ag-specific IgG1
and IgG2a responses when immunized in Complete Freund’s
Adjuvant (CFA). Therefore, B7-1 and B7-2 can have over-
lapping compensatory functions for IgG production. How-
ever, when immunized intravenously with Ag in PBS, B7-2-
deficient mice failed to produce Ab, whereas B7-1-deficient
mice gave normal Ab responses. These data indicate that
although B7-2 and B7-1 have compensatory roles, B7-2 is
more dominant.32
B7-1 and B7-2 may differentially affect Th1/Th2 cell
development
A number of in vitro studies have indicated an important role
for B7-1 and B7-2 in the differentiation of Th1 and Th2 cells.
For example, Freeman et al. have found that repetitive 
costimulation of naïve T cells, with CHO cells expressing
B7-2, results in moderate levels of IL-4 and IL-2 production.7
In contrast, repetitive costimulation with CHO cells express-
ing B7-1 results in high levels of IL-2 and low levels of IL-4
production. Similarly, Kuchroo et al. have found that when
naïve myelin basic protein (MBP)-specific TCR transgenic T
cells are activated in vitro in the presence of anti-B7-1 or
anti-B7-2 mAb, Th2 or Th1 cytokine profiles, respectively,
are produced.91 These two studies indicate that B7-1 signals
preferentially promote development of Th1 cells, while B7-2
signals promote Th2 cell development.
Other in vitro studies have failed to identify any difference
between B7-1 and B7-2 in driving Th1 or Th2 differentiation.
For example, Lanier et al. have found that both B7-1 and B7-
2 transfectants can stimulate resting human peripheral blood
T cells to secrete IL-2 and IFN- g or to differentiate into cyto-
toxic T lymphocytes.92 However, neither B7-1 nor B7-2
promote the development of IL-4-secreting T cells. Moreover,
Anderson et al. have recently demonstrated that both B7-1 and
B7-2 CHO transfectants increase proliferation and cytokine
secretion following activation of a Th2 clone.93 Only B7-1 can
provide the costimulatory signals required for activation of the
Th2 clone by a weak peptide agonist, whereas both B7-1 and
B7-2 induce activation to a strong peptide agonist. Based on
this data, Anderson and colleagues have suggested that it is
necessary to decrease the strength of the TCR signal to see
differences in B7-1 and B7-2 costimulation.
In vivo studies have also indicated differential roles for
B7-1 and B7-2 in the differentiation of Th1 and Th2 cells. As
discussed earlier, Kuchroo et al.91 have proposed a role for
B7-1 and B7-2 during in vitro Th1 and Th2 cell differentia-
tion and, using a model of experimental autoimmune
encephalomyelitis, have suggested that B7-1 and B7-2
promote in vivo Th1 and Th2 cell responses, respectively. In
this system, treatment with anti-B7-1 mAb reduces the inci-
dence of disease by promoting Th2 cell development. Con-
versely, treatment with anti-B7-2 mAb increases disease
severity by promoting the development of Th1 cells.
A study by Lenschow et al.94 has investigated the roles of
B7-1 and B7-2 costimulation using an autoimmune model of
diabetes, mediated by Th1 cells. These authors have shown
that blockade of B7-1 costimulation increases disease inci-
dence, presumably by increasing development of Th1 cells.
Blockade of B7-2 costimulation prevents the onset of 
diabetes by down-regulating Th1 cell responses. This study
indicates that B7-1 and B7-2 promote Th2 and Th1 cell
responses, respectively, and is in direct contrast to the data
obtained in the EAE model. However, regardless of whether
B7-1 and B7-2 costimulation directly modulates Th1/Th2 
differentiation, the Kuchroo and Lenschow studies establish
that B7-1 and B7-2 can have differential effects on the T cell
immune response.91,94
Potential mechanisms for differential regulation of 
T cell immune responses by B7-1 and B7-2
There are a number of mechanisms by which B7-1 and B7-2
costimulatory ligands may have a differential effect on T cell
immunity. For example, B7-1 and B7-2 may engage CD28 in
distinct ways, resulting in differences in CD28 signal trans-
duction. Two studies that have examined the effects of B7-1
and B7-2 costimulation have failed to find any significant
differences in the activation of T cell second messengers or
cytokine production.92,95 Alternatively, engagement of B7-1
or B7-2 could lead to alterations in APC function. Indeed, the
possibility that B7-2 may function as a signalling molecule is
supported by the finding that B7-2 is phosphorylated follow-
ing B-cell activation.34 Based on the relative timing of their
expression, B7-2 may be the physiological ligand for CD28
and B7-1 the primary ligand for CTLA-4. However, Linsley
et al.29 have failed to find any evidence for preferential
binding of CD28 and CTLA-4 to B7-1 or B7-2.
B7-1 and B7-2 may differentially alter the immune
response simply due to variation in their expression. In
support of this hypothesis, Miller et al. have noted preferen-
tial up-regulation of B7-1 during relapsing EAE and a selec-
tive increase in its functional costimulatory activity relative to
B7-2.96 Similarly, Windhagen et al. have reported a selective
up-regulation of B7-1 in patients with multiple sclerosis.97
Our own studies have indicated that B7-1 costimulation is
required for the induction of optimal airway eosinophil
inflammatory responses in OVA-immunized and airway-
challenged mice, while it is not necessary for OVA-specific
Ab production or blood eosinophilia.98 These data may indi-
cate that B7-1 costimulation is more stringently required for
activation in the peripheral tissues, such as lung, than in the
lymphoid tissues. However, this is not due to selective
expression of B7-1 by lung APC. Alternatively, there may be
a requirement for more potent T-cell activation in the lym-
phoid tissues before peripheral inflammation can occur or a
selective role for B7-1 costimulation in allowing T-cell
migration into the periphery.
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